Catalog No.
KAV13102
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant MPXV A35R antigen has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Human Anti-MPXV A35R IgG present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Human Anti-MPXV A35R IgG bound in the initial step. The color development is stopped and the intensity of the color is measured.
Target
A35R
Applications
Used for the quantitative determination of Human Anti-MPXV A35R IgG concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.63 - 20 ng/mL
Sensitivity
0.62 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
9.6
|
2.5
|
1.3
|
11.3
|
2.9
|
0.8
|
|
Standard deviation
|
0.4
|
0.1
|
0.0
|
0.4
|
0.2
|
0.1
|
|
CV (%)
|
4.0
|
2.4
|
2.8
|
3.6
|
5.5
|
10.4
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.
A Single-Chain Mpox mRNA Vaccine Elicits Protective Immune Response in Mice., PMID:40432124
A Pathogen-Mimicking Monkeypox Virus Nanovaccine Inspired by Assembly of Viral Antigens with β-Glucan and Dendrimer., PMID:40366370
Current status of next-generation vaccines against mpox virus: a scoping review., PMID:40356988
Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice., PMID:40105863
Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development., PMID:39994775
Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein., PMID:39861905
Long-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice., PMID:39726255
A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates., PMID:39639037
Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus., PMID:39423738
Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines., PMID:39417768
Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus., PMID:38787725
Levels of antibodies against the monkeypox virus compared by HIV status and historical smallpox vaccinations: a serological study., PMID:38767199
In silico development of a novel anti-mutation, multi-epitope mRNA vaccine against MPXV variants of emerging lineage and sub-lineages by using immunoinformatics approaches., PMID:38450722
Screening, Expression and Identification of Nanobody Against Monkeypox Virus A35R., PMID:38076734
Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice., PMID:37800627
Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history., PMID:37784185
A Subunit Vaccine Candidate Composed of Mpox Virus A29L, M1R, A35R, and B6R Elicits Robust Immune Response in Mice., PMID:37766097
mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge., PMID:37739969
Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus., PMID:37709783
Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge., PMID:37435062
Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice., PMID:37429529
Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review., PMID:37353117
Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus., PMID:37288876
Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus., PMID:37117161
Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches., PMID:36993967
Rational development of multicomponent mRNA vaccine candidates against mpox., PMID:36947428
Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens., PMID:36687315
For research use only. Not for human or drug use.
